Astellas Pharma Inc
TSE:4503

Watchlist Manager
Astellas Pharma Inc Logo
Astellas Pharma Inc
TSE:4503
Watchlist
Price: 1 521 JPY -0.62% Market Closed
Market Cap: 2.8T JPY
Have any thoughts about
Astellas Pharma Inc?
Write Note

Astellas Pharma Inc
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Astellas Pharma Inc
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Astellas Pharma Inc
TSE:4503
Other Current Liabilities
ÂĄ624.9B
CAGR 3-Years
23%
CAGR 5-Years
18%
CAGR 10-Years
15%
Takeda Pharmaceutical Co Ltd
TSE:4502
Other Current Liabilities
ÂĄ1.3T
CAGR 3-Years
0%
CAGR 5-Years
3%
CAGR 10-Years
11%
Daiichi Sankyo Co Ltd
TSE:4568
Other Current Liabilities
ÂĄ140.7B
CAGR 3-Years
41%
CAGR 5-Years
25%
CAGR 10-Years
8%
Otsuka Holdings Co Ltd
TSE:4578
Other Current Liabilities
ÂĄ373.1B
CAGR 3-Years
15%
CAGR 5-Years
13%
CAGR 10-Years
6%
S
Shionogi & Co Ltd
TSE:4507
Other Current Liabilities
ÂĄ96.9B
CAGR 3-Years
8%
CAGR 5-Years
13%
CAGR 10-Years
7%
Chugai Pharmaceutical Co Ltd
TSE:4519
Other Current Liabilities
ÂĄ150.3B
CAGR 3-Years
12%
CAGR 5-Years
15%
CAGR 10-Years
14%
No Stocks Found

Astellas Pharma Inc
Glance View

Market Cap
2.7T JPY
Industry
Pharmaceuticals

Astellas Pharma Inc., a beacon in Japan's pharmaceutical landscape, weaves its narrative from a rich tapestry of innovation and strategic acumen. Born from the 2005 merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas quickly established itself as a global powerhouse based in Tokyo. The company operates primarily by investing heavily in R&D to drive breakthroughs in life sciences, particularly focusing on therapeutic areas like oncology, urology, immunology, and transplant-related therapies. Through these focal points, Astellas channels its resources to cultivate novel treatments that address unmet medical needs, thereby enhancing the quality of life for patients worldwide. The financial architecture of Astellas Pharma is underpinned by its strategic prowess in expanding its product pipelines and leveraging partnerships to amplify its reach. Revenue generation primarily hinges on its robust product offerings, spearheaded by successful medications such as XTANDI for prostate cancer and Prograf, which aids in organ transplantation outcomes. This diversified product portfolio is complemented by an astute approach to global market penetration, where Astellas not only markets these pharmaceuticals but also strategically collaborates with biotech firms and research institutions to harness cutting-edge technologies. This business model not only propels profitability but also ensures that Astellas remains at the forefront of medical innovation, positioning itself as a pivotal entity within the pharmaceutical industry.

Intrinsic Value
1 752.54 JPY
Undervaluation 13%
Intrinsic Value
Price

See Also

What is Astellas Pharma Inc's Other Current Liabilities?
Other Current Liabilities
624.9B JPY

Based on the financial report for Sep 30, 2024, Astellas Pharma Inc's Other Current Liabilities amounts to 624.9B JPY.

What is Astellas Pharma Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
15%

Over the last year, the Other Current Liabilities growth was 4%. The average annual Other Current Liabilities growth rates for Astellas Pharma Inc have been 23% over the past three years , 18% over the past five years , and 15% over the past ten years .

Back to Top